Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes

Table 4 Univariate analysis to identify independent factors for the incidence of TLR

	Univariate
	Odds ratio	95% CI	p value
Hypertension	0.820	0.093–7.225	0.858
Dyslipidemia	0.399	0.073–1.565	0.166
Chronic kidney disease	0.795	0.169–3.745	0.771
Hemodialysis	10.370	2.104–51.108	0.004
Smoking	0.730	0.084–6.369	0.776
Previous myocardial infarction	1.668	0.362–7.692	0.512
Previous PCI	0.410	0.079–2.138	0.290
Type B2/C lesion	2.040	0.382–10.906	0.404
Chronic total occlusion	3.813	0.687–21.156	0.126
Rotational atherectomy	5.920	0.998–35.112	0.050
Small stent (≤ 2.5 mm)	0.851	0.185–3.917	0.836
Long stent (≥ 30 mm)	0.861	0.188–3.936	0.847
Multiple stent	1.634	0.357–7.469	0.527
BP-SES usage	6.686	1.234–36.217	0.028
ACEI/ARB	0.738	0.136–3.989	0.724
Beta blocker	0.617	0.133–2.872	0.539
Statin	1.128	0.129–9.829	0.913
Insulin	3.455	0.723–16.522	0.120

ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, BP-SES biodegradable polymer sirolimus-eluting stent, CI confidence interval, PCI percutaneous coronary intervention, TLR target lesion revascularization

ISSN: 1475-2840